Cencora delivered calendar Q3 2026 results that aligned with market expectations on revenue and topped analyst profit forecasts. Management credited the quarter’s performance to strong growth in specialty pharmaceuticals, driven by recent acquisitions such as OneOncology and the expansion of its management services organization (MSO) platform. CEO Bob Mauch highlighted these investments as central to Cencora’s ability to support pharmaceutical-centric care, noting increased activity in specialty biologics and community-based care partnerships. The company also pointed to operational improvements and focused execution across its core distribution businesses as key contributors.

Is now the time to buy COR? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from Cencora’s Q3 earnings call

• Elizabeth Anderson (Evercore ISI) asked why Cencora reorganized its segments now. CEO Bob Mauch explained it aligns leadership and assets for better execution and customer focus amid specialty market growth.
• Lisa Gill (JPMorgan) questioned organic growth drivers and reimbursement risks in specialty. Mauch stated Cencora is well-placed across care settings and maintains flexibility to adapt to policy changes, while CFO Eva Boratto clarified MSO acquisition timing boosts near-term growth above the long-term algorithm.
• Glen Santangelo (Barclays) asked about margin dynamics and the impact of biosimilar conversions. Boratto explained specialty margins remain higher due to a mix of distribution, MSO, and logistics, but acknowledged biosimilar launches are positive for profit but less impactful in certain Medicare segments.
• Charles Rhyee (TD Cowen) inquired about generic cycles and their influence on distribution segment growth. Mauch said generic and biosimilar launches are incorporated in guidance and generally benefit Cencora, but the company is not forecasting a major shift in launches as a driver.
• Allen Lutz (Bank of America) asked about strategic synergies from bringing clinical trial logistics and MSOs together. Mauch described the integration as a growth-focused move, enabling end-to-end support for pharmaceutical partners from clinical trials to community-based care.

Catalysts in upcoming quarters

In the coming quarters, our analysts will monitor (1) the pace and impact of MSO and specialty asset integration, (2) execution on the new segment structure and its effect on operational efficiency, and (3) the progression of planned divestitures and the MWI Animal Health–Covetrus merger. We will also track the effect of new specialty product launches and related reimbursement changes.

Cencora currently trades at $349.99, up from $340.50 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).

Our favorite stocks right now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.